Surabhi Dangi-Garimella, PhD

Is rubber meeting the road with big data in cancer care? “No…rather, not yet,” Green said at the 2017 Community Oncology Conference, April 26-27, held at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

Community oncologists believe that they are in a very good position to lead the way to achieve the goals of Cancer Moonshot.

At the 2017 Community Oncology Conference, practice administrators from 2 community clinics discussed the changes they made to their practice to accommodate the reporting requirements of the Oncology Care Model (OCM), and the follow-up planned as they work to implement changes.

At the 2017 Community Oncology Conference, participants discussed the impact of pharmacy benefit managers (PBMs) on oncology drug prices and patient access to much needed treatments.

A study evaluating a patient-reported outcomes measure tool in patients who had undergone colorectal surgery recommends using the tool for preoperative counseling prior to surgery.

Eli Lilly and Company has announced that abemaciclib improved progression-free survival (PFS) when combined with an aromatase inhibitor (AI), compared with AI alone, in patients with breast cancer.

The University of Connecticut has initiated recruitment for a phase I trial to test the safety and efficacy of OncoImmunome, a personalized vaccine designed to prevent relapse in patients diagnosed with Stage III or IV ovarian cancer.

At this year’s meeting, themed Fueling the Cancer Moonshot, attendees will gain a better understanding of strategies for success within the community oncology realm.

Although the purpose of eligibility criteria is to protect patients from unnecessary harm, define the study population, and allow researchers to collect safety and efficacy data for a specific population, unnecessary restriction may not capture the heterogeneity of real-world patients.

The approval of the Paxman Scalp Cooling System follows a randomized clinical trial, whose results were published in JAMA following an interim analysis.

The American Society of Clinical Oncology (ASCO) has raised concerns that utilization management strategies, especially for high-cost prescription drugs, could reduce patient access.

JAMA study highlights need for considering patient preferences when choosing between treatment options for prostate cancer.

The approval comes following phase 2 results of 119 patients who participated in the IMvigor210 study.

A study published in The Oncologist concluded that discrepant variant classification in public databases can introduce uncertainty and diminish patient care.

Study identifies need for surgeons to maximize benefits of genetic testing for surgical decisions in breast cancer.

Exposure to tobacco smoke as a fetus or during early childhood can cause genetic changes that can increase a child’s risk of developing acute lymphoblastic leukemia (ALL).

A new study published in Clinical Cancer Research provides evidence that researchers can use biomarkers to identify patients whose tumors will grow at a faster rate following immunotherapy treatment.

A study presented at the annual meeting of the American Association for Cancer Research predicts a shift in the number and the pattern of cancer incidence among those infected with the human immunodeficiency virus (HIV).

The American Society of Clinical Oncology (ASCO) has released a statement raising serious concerns about right to try, while strongly supporting the FDA’s expanded access program.

Following news of a global recall of batches of EpiPen, Mylan NV has also been hit with a class action lawsuit claiming the company struck a deal with pharmacy benefit managers (PBMs) over the price of the life-saving medication.

The 5-year survival estimate from a study evaluating nivolumab in a subset of patients with advanced non-small cell lung cancer (NSCLC) is significantly longer following treatment discontinuation.

The full approval comes in less than 2 years of the drug's accelerated approval by the FDA.

Being blind, intellectually disabled, or having a spinal cord injury can reduce the probability of a person being screened for colorectal cancer.

Will Scott Gottlieb's pharma consulting experience be a boon in disguise for the FDA?

A study published in the journal Cancer has found that the rate of advanced imaging at the time of breast cancer diagnosis reduced during the period between 2008 and 2015 in the state of Michigan.

Results from the randomized NOVA trial convinced the FDA to approve niraparib (Zejula) as maintenance treatment for adult patients with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who are sensitive to platinum-based chemotherapy.

According to research conducted at the Colorado School of Public Health at CU Anschutz, nearly 75% of smokers have low socioeconomic status.

At the 22nd Annual Conference of the National Comprehensive Cancer Network, held March 23-25, 2017, in Orlando, FL, Gregory J. Riely, MD, PhD, Memorial Sloan Kettering Cancer Center, spoke about the what, when, and how of biomarker testing in non-small cell lung cancer.

On the second day of the 22nd Annual Conference of the National Comprehensive Cancer Network (NCCN), Kilian E. Salerno, MD, of the Roswell Park Cancer Institute, walked the audience through updates to the NCCN Guidelines, explaining clinical situations in which radiation is indicated, appropriate targets of radiation treatment, and optimal approaches for minimizing toxicity.

While multigene panels are extremely important in precision cancer care, high levels of variance and insufficient insurance coverage are significant barriers to rapid adoption, according to Kenneth Offit, MD, MPH, from Memorial Sloan Kettering Cancer Center.